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Introduction
Cancer cells display a set of heterogeneous characteristic features including uncontrolled cell division, clonal expansion, intravasation and extravasation in the blood and lymphatic vessels, and metastasis to invade different tissues. 1 Growth factor receptors, which are expressed on the cell surface and in the cytoplasm of tumours, are associated with tumour development, progression, angiogenesis and metastasis. 2, 3 Overexpressed growth factor receptors are considered to be tumour biomarkers, which can be used as targets for tumour diagnosis and/or therapeutic targeting. Examples include vascular endothelial growth factor (VEGF), 4 epidermal growth factor (EGF), 5 and fibroblast growth factor (FGF), 6 which have been targeted by anticancer therapies against bladder, prostate, colorectal and breast cancers.
Over the past few decades, research has suggested that bombesin (BBN) family peptides act as growth factors for various cancers including breast, colon, prostate and small cell lung cancer. 2 Bombesin is a tetradecapeptide which was first isolated from the skin of the Bombina bombina frog in 1972. 7 Since its initial isolation, extensive investigations have been conducted, which have provided valuable insights into the function of BBN and its corresponding receptors. 8 Three types of mammalian BBN receptors have been identified:
gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype-3 (BRS-3). Each of these receptors belongs to the G-protein coupled receptor super family. 9 Bombesin and its mammalian counterpart gastrin-releasing peptide (GRP) have structural and functional similarities. The 27-amino acid long peptide, GRP, was first identified from porcine gut in 1979. 10 Both BBN and GRP share a homologous C-terminal seven amino-acid long sequence Trp-Ala-Val-Gly-His-Leu-Met-NH 2 , 8 which is important for receptor binding and internalisation. 9 Due to this similarity, BBN and GRP exert similar physiological effects.
For example, both peptides function as a gastrointestinal hormone and as a neurotransmitter. 8, 11 In addition, they are both mitogens, and function as autocrine growth factors for tumour cells. 8, 12, 13 The GRP receptor is overexpressed in a wide range of cancers, including: glioblastomas, small cell lung, gastric, pancreatic, prostate, breast, cervical, and colon cancers, whereas NMBR and BRS-3 are expressed in a limited number of carcinomas. [14] [15] [16] [17] (6) (7) (8) (9) (10) (11) (12) (13) (14) ] to investigate whether the shorter, more serum stable, 24, 25 and more readily synthesised BBN (6) (7) (8) (9) (10) (11) (12) (13) (14) peptide is as effective for GRPR targeting as the full length peptide. Further, the capacity for these peptides to be internalised by receptor mediated cellular internalisation has been studied using 5(6)-carboxyfluorescein fluorescently tagged BBN peptides. Prior to evaluating the cellular uptake of each analogue, the level of GRPR expression in a library of cancerous (Caco-2, HeLa, LNCap, MDA-MB-231, and PC-3) and immortalised primary cell lines (WPMY-1) was evaluated by western blotting. Quantitative (flow cytometry) and qualitative (confocal microscopy) cell uptake studies were then conducted to evaluate the level of cellular internalisation and the intracellular localisation of each BBN peptide. To evaluate the mechanism of internalisation competitive, and temperature dependent cell uptake studies were conducted. A major aim of this study was to compare the capacity to target GRPR expressing cancer cell lines using BBN peptides as a means to improve the targeted delivery of anticancer therapeutics. Toward this goal, a comparison of cellular uptake in breast (MDA-MB-231), colon (Caco-2), prostate (PC-3) and cervical cancer (HeLa) cell lines was performed using both BBN peptide analogues. 2 Results and discussion
BBN Peptide synthesis and characterisation
Each peptide (1-4) was successfully synthesised using manual solid phase peptide synthesis.
The fluoresecent tag 5(6)-carboxyfluorescein (FAM), was coupled to the N-terminus of peptides 1 and 2 through a lysine spacer to produce compounds 3 and 4 using 1-hydroxybenzotriazole (HOBt) and N,N'-diisopropylcarbodiimide (DIC) as coupling reagents.
Coupling was performed in the dark to minimise photo bleaching, followed by the removal of any ester linked FAM by repeateted 20% piperidine washing (5 min each cycle) until no further color was observed when washed. The peptides were cleaved from the resin using trifluoroacetic acid (TFA) in the presence of 2.5 % 1,2-ethanedithiol (EDT) to minimize methionine oxidation to methionine sulfoxide. 26 The crude peptides were purified by reversed phase-high performance liquid chromatography (RP-HPLC) to > 99% purity using water/acetonitrile gradients ( Table 1 ). The purified fractions were lyophilised to yield the final pure compounds 1-4, which were characterised by RP-HPLC and electrospray ionization-mass spectroscopy (ESI-MS) ( Supplementary Fig. 1 ). Purification and characterisation data (RP-HPLC and MS) are presented in Table 1 . 
Analysis of GRPR expression by western blotting
Western blotting was performed to investigate the level of GRPR expression in various human tumour-derived (HeLa, PC-3, MDA-MB-231, LNCaP, and Caco-2) and immortalized non-tumour-derived (WPMY-1) cell lines. Cell lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer, and the protein content for each group quantified using a bicinchoninic acid (BCA) assay. Equivalent amounts (15 µg/lane) of total protein from each cell line were separated by SDS-PAGE on a 10% gel, electrotransferred onto a PVDF membrane, and probed using a polyclonal rabbit α-GRPR antibody (Abcam ab39963). GRPR bands were then detected using enhanced chemiluminescence (ECL) after probing with a goat α-rabbit IgG-peroxidase conjugate (Sigma A6154) secondary antibody.
Caco-2 cells were used as a positive control for GRPR expression, as recommended by the antibody manufacturer, with glyceraldehyde-3-phosphate dehydrogenase (GADPH) staining used as a loading control. 27 Each of the cell lines tested was observed to express GRPR by western blotting ( Fig. 2A ).
The highest level of GRPR expression was observed in the PC-3 prostate cancer epithelial cell line, with the Caco-2 colon cancer epithelial cell line demonstrating the lowest level of GRPR expression ( Fig 
Analysis of the cellular uptake of BBN peptides by flow cytometry
In order to evaluate how effectively BBN peptides are internalised by GRPR expressing cells, the cellular uptake of fluorophore-labelled BBN peptides 3 and 4 was evaluated by flow cytometry in PC-3 cells at three different concentrations (1, 5, and 10 μM). Trypan blue was used to quench any fluorescence associated with surface bound peptides prior to analysis by flow cytometry (with the results reported as intracellular fluorescence in Fig. 3 ) in order to differentiate between peptides that are associated with the surface of PC-3 cells, and peptides that were internalised. 28 This experiment demonstrated that the percentage of PC-3 cells containing internalised BBN peptides 3 or 4 increased as the concentration of each peptide was increased (from 1.76% to 29.8% and from 1.86% to 29.7% at 1 and 10 µM for both compound 3 and 4, respectively), with comparible results observed at each tested concentration for peptides 3 and 4 (p > 0.05) (Fig. 3A) . This data indicated that the truncated BBN(6-14) peptide 3, which is easier and less expensive to synthesize in comparison to the full-length BBN peptide 4, would be preferable for incorporation into GRPR-targeted delivery systems. To gain additional insight into the mechanism of cellular uptake, the cell uptake experiment was repeated at 4 °C, a temperature at which energy-dependent endocytosis is inhibited.
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Comparing the percentage FAM-positive cells after incubating PC-3 cells with peptides 3 or 4 at 4 °C and 37 °C revealed that the cellular uptake of both peptides was significantly reduced at 4 °C (p < 0.01; Fig. 3B ). The percent FAM-positive cells ranged from 20-22% for each peptide at 37 °C, and were reduced to 2-4% at 4 °C, suggesting that BBN cellular uptake is predominantly associated with energy dependent pathways.
Competative cell uptake study
Because fluorescein analogs have been demonstrated to be internalised by cultured cells, 30 including conjugates with high molecular weight polymers, 31, 32 we wanted to demonstrate that the observed internalisation of peptides 3 and 4 was due to BBN and not the FAM-label.
This was achieved by conducting the uptake assay in PC-3 cells with peptides 3 or 4 (5 μM)
in the presence of a 10× excess of the unlabelled BBN peptides 1 or 2. If the BBN peptides were responsible for cellular uptake, rather than the FAM-label, the excess of peptides 1 or 2 would compete for uptake, and a large reduction in the uptake of 3 or 4 would be observed by flow cytometry. This outcome was observed, with the incubation of PC-3 cells with FAMlabelled peptides 3 and 4 exhibiting only 4 and 2% FAM-positive cells respectively in the presence of a 10× excess of peptides 1 or 2 (Fig. 3C ). In comparison, where PC-3 cells were not exposed to peptides 1 or 2, 47 and 42% FAM-positive cells respectively were observed (Fig. 3C) . This experiment strongly supported the hypothesis that cellular uptake of peptides 3 and 4 was due to BBN, and not the FAM-label. In addition, since the uptake process was energy dependent, and could be competed with BBN peptides, this data suggested that the uptake of peptides 3 and 4 was associated with BBN receptors. The data also demonstrated that N-terminal modification of BBN peptides is compatible with BBN receptor targeting and cellular uptake, and thus may serve as a modification site for targeting therapeutics to cells that overexpress GRPR.
Comparing the uptake of bombesin peptides in different GRPR-expressing cell lines
In this report western blotting was used to assess the level of GRPR expression in a library of (Fig. 4) . This data was in direct agreement with the GRPR expresion levels detected by western blotting of lysates for each of the assessed cell lines ( Fig. 2A) , and thus suggests that the level of BBN peptide uptake is proportional to the level of GRPR expression. As such, BBN peptides may prove useful for targeted prostate cancer therapies. 
Confocal imaging of the internalisation of FAM-labelled BBN peptides 3 and 4 in PC-3 cells
To provide additional supporting evidence for the uptake of FAM-labelled BBN peptides 3 and 4 in PC-3 cells, live cell confocal microscopy was used to detect internalised peptides and to probe their subcellular localisation. For this experiment, the cells were incubated for 4 h with peptides 3 or 4 at 5 μM concentrations, washed, and stained with: Trypan blue to quench surface-associated fluorescence; Hoechst 33342 to label the nucleus; and LysoTracker ® Red DND-99 to label endo(lyso)somes. Intracellular FAM-associated fluoresence was observed at 5 μM concentration for both peptides 3 and 4, with fluorescence distributed throughout the cytoplasm (Fig. 5) . The presence of punctate staining, colocalised with the LysoTracker dye (which stains acidic organelles, i.e. endo(lyso)somes) 33 suggests that BBN peptides are likely internalised by an endocytic pathway, with some entrapment in endosomes. Overall, this data demonstrates that the BBN peptides can be internalised by PC- Untreated PC-3 cells were used as a negative control (neg. ctl.). Imaging was performed at 63× magnification, using an oil emersion lens.
Conclusion
The tissue-specific targeting of therapeutic molecules provides a useful means to improve drug efficacy by enabling reductions in the dose of therapeutic molecules that are delivered, and offering the potential to reduce adverse effects. These advantages of targeted drug delivery are of immense interest for the treatment of various cancers. Herein, we aimed to characterise the potential of GRPR, which is overexpressed on many types of tumours, to be targeted by BBN peptides in order to improve the targeted delivery of anticancer therapeutics.
A key finding from this work was the evaluation of GRPR expression on a library of different Further, both BBN analogues (3 and 4) were observed to exhibit similar internalisation by flow cytometry and confocal microscopy. This data therefore suggests that the truncated BBN(6-14) peptide, owing to its shorter sequence, would be preferable for incorporation into GRPR targeted drug delivery systems. Finally, the ability to competitively inhibit the uptake of labelled BBN peptides with unlabelled BBN peptides or reduced temperatures suggested that the uptake of these peptides was through GRPR rather than non-specific mechanisms.
Overall, the information gained herein on GRPR expression levels and the uptake of BBN peptides in various cancerous and non-cancerous cell lines will prove of great utility for the engineering of GRPR targeted drug delivery systems, and for the in vitro assessment of their targeting capacity.
Experimental

Materials
All chemicals used were of analytical grade or equivalent, unless otherwise noted. Rink 
Equipment
Analytical RP-HPLC analysis was conducted using a Vydac C18 analytical column (218TP54, 5 µm, 4.6 x 250 mm) at 1 mL/min flow rate with detection at 214 nm using linear gradients over 30 min as described in table 1. Preparative HPLC was performed using a 
Solid phase peptide synthesis
Peptides 1-4 ( 
Purification and characterisation
Each crude peptide was purified by RP-HPLC on a Vydac C18 column (218TP1022, 22 mm x 250 mm) at 20 mL/min using solvent B gradients over 30 min (Table 1 ) with detection at 214 nm. Each fraction was analysed for purity by analytical HPLC on a Vydac C18 column (218TP54, 4.6 mm × 250 mm, 5 µm) using the same gradient over the same duration used for purification. Fractions that contained pure peptide were combined and lyophilised to yield pure peptides 1-4. Each peptide was characterised by RP-HPLC for purity and ESI-MS for identity (Table 1) .
Cell culture
Human To quench any cell surface bound fluorescence, the cells were treated with trypan blue to 0.1 % final concentration 2 min prior to analysis by flow cytometry (BD Accuri C6 flowcytometer, 488 nm excitation and 515-545 nm emission filter). Each assay was carried out in triplicate and 10,000 events were collected.
The effect of temperature on cellular uptake
To further investigate the mechanism of uptake for peptides 3 and 4, energy-dependant endocytosis was inhibited by conducting the uptake assay 4.7.1 at 4 °C, and comparing the results with uptake at 37 °C using flow cytometry. For the 4 °C group, the cells were incubated at 4 °C for 30 min prior to performing the uptake experiment. 
